EGFR and non-small cell lung carcinoma: This notion has paved the way for the development of orally-active EGFR tyrosine kinase inhibitors (TKIs), for example, Gefitinib (Iressa®), which binds the adenosine triphosphate (ATP) pocket in the EGFR catalytic domain without affecting insulin receptor tyrosine kinase activity, as a first-line targeted therapy for NSCLC [49,50].